The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis

Abstract

Background and aimIn cystic fibrosis, gastrointestinal dysfunction and lower airway infection occur early and are independently associated with poorer outcomes in childhood. This study aimed to define the relationship between the microbiota at each niche during the first 2 years of life, its association with growth and airway inflammation, and explanatory features in the metabolome.Materials and methods67 bronchoalveolar lavage fluid (BALF), 62 plasma and 105 stool samples were collected from 39 infants with cystic fibrosis between 0 and 24 months who were treated with prophylactic antibiotics. 16S rRNA amplicon and shotgun metagenomic sequencing were performed on BALF and stool samples, respectively; metabolomic analyses were performed on all sample types. Sequencing data from healthy age-matched infants were used as controls.ResultsBacterial diversity increased over the first 2 years in both BALF and stool, and microbial maturation was delayed in comparison to healthy controls from the RESONANCE cohort. Correlations between their respective abundance in both sites suggest stool may serve as a noninvasive alternative for detecting BALFPseudomonasandVeillonella. Multisite metabolomic analyses revealed age- and growth-related changes, associations with neutrophilic airway inflammation, and a set of core systemic metabolites. BALFPseudomonasabundance was correlated with altered stool microbiome composition and systemic metabolite alterations, highlighting a complex gut–plasma–lung interplay and new targets with therapeutic potential.ConclusionExploration of the gut–lung microbiome and metabolome reveals diverse multisite interactions in cystic fibrosis that emerge in early life. Gut–lung metabolomic links with airway inflammation andPseudomonasabundance warrant further investigation for clinical utility, particularly in non-expectorating patients.